On Feb 12, 2014, Protalix released the highly anticipated Phase I clinical data on its oral drug candidate for Gaucher's disease, PLX-112. Phase I studies were completed in 4Q2013 and are being presented at the Lysosomal Disease conference in San Diego on Feb 12. Nearly all therapeutic proteins are delivered via injection since the proteins are not stable in the highly acidic stomach. Using their proprietary plant-based technology, Protalix has developed an oral formulation that protects proteins in their journey through stomach and then are released in the milder pH conditions of the intestine by digestive enzymes secreted by the pancreas. PRX-112 is their first oral therapy to reach Phase I and demonstrating oral bioavailability in humans is a very...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|